Investigational Drug Use
What is investigational drug use?
Investigational drug use is the use of an investigational medicine when you are seriously ill but not enrolled in a clinical trial. Investigational medicines are in the process of being studied but have not yet been approved as safe and effective by the U.S. Food and Drug Administration (FDA). It is sometimes called compassionate drug use.
Normally, investigational medicines undergo strict testing through many stages of clinical trials before they are available to the public. They are tested for safety, side effects, how well they work and at what doses, and with what conditions or diseases they are to be used. The process may take up to many years. Under certain circumstances, these medicines can be used outside of a clinical trial.
Investigational drug use is legal and a fairly new practice. The FDA first approved investigational medicines to be used in this way for critically ill patients in 1987.
Who is eligible to use these medicines?
The most common way people access unapproved medicines is by enrolling in a clinical trial. This is the safest route. The FDA closely regulates clinical trials, and people taking new medicines are carefully watched. However, not everyone will qualify for a clinical trial. Because the use of new, unapproved medicines is risky, only certain people who are not enrolled in clinical trials can receive investigational medicines for compassionate use. According to guidelines from the National Cancer Institute (NCI), you are eligible if you:
Have used standard treatments and found them unsuccessful
Are ineligible for any ongoing clinical trials
Have no acceptable treatment options
Have a cancer diagnosis for which an investigational medicine has shown some benefit and is currently being studied in clinical trials
Are likely to have benefits that outweigh the risks involved
Accessing investigational medicines
To use investigational medicines, your healthcare provider has to apply for it through a treatment investigational new drug application (Treatment IND). The application process includes information on your condition and past treatments.
The most common way to get approval for an investigational medicine outside of clinical trials is through expanded access or special exception or single-patient exception.
Expanded access uses medicines that have been well-tested and are nearing FDA approval. The medicine must show in studies that it is effective in treating a specific cancer. The program is offered by a medicine company and the medicine is given out to a group of people.
Special exceptions are individual requests (usually by a healthcare provider) made to medicine companies or to whomever is overseeing a program or clinical trial. The decision to give out the medicine is weighed on a case-by-case basis. There must be some proof that the medicine would either improve the patient's quality of life or lengthen his or her life.
Risks of using investigational medicines
There are drawbacks to compassionate drug use for you and for the drug approval process. One is that they may interfere with clinical trials if more people seek this route rather than participating in trials. Although the NCI gathers some safety information on investigational-use drugs, it is not as helpful in getting FDA approval of these medicines. You are not watched as closely as you would be if you were part of a clinical trial.
Other problems include the chances of receiving no lasting benefit from the medicine, undiscovered harmful side effects, and extra costs not covered by health insurance that may be associated with using the medicine.
For more information
To learn more about investigational medicines and clinical trials, talk with your healthcare provider about your options, the risks and side effects of the medicine under consideration, and what the process is to apply to use the medicine. Clear communication with the healthcare provider who treats you is important. Together, you can determine whether a clinical trial or compassionate use is right for you.
Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) or visit www.clinicaltrials.gov to search for clinical trials for your condition.
If you don't qualify for a clinical trial, your healthcare provider can ask the trial's sponsor about requesting a single-patient exception. He or she may also contact the NCI or the company making the medicine to find out if expanded access programs exist.